Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model - PubMed (original) (raw)

Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model

K Kimura et al. Cancer Immunol Immunother. 2000 May.

Abstract

Interleukin(IL)-15, which uses IL-2 receptor (R) beta and gamma chains for signal transduction, shares many of the biological activities of IL-2. We examined the effects of exogenous IL-15 on protection in a murine malignant pleurisy model using BALB/c mice and syngeneic MethA fibrosarcoma (MethA). Intrapleural administration of IL-15 significantly prolonged the survival time of mice after an intrapleural inoculation of MethA, whereas the same dose of IL-2 did not. The in vivo antitumor effect of IL-15 was synergistically enhanced by additive administration of IL-12. Combination therapy of IL-15 and IL-12 protected mice from death from bloody pleural fluid. Such treatment induced marked increases in the number of CD3-IL-2Rbeta+ cells corresponding to natural killer (NK) cells and the production of interferon gamma (IFNgamma) by T cells in the thoracic exudate cells (TEC). Administration of anti-IFNgamma mAb partly inhibited the protective effect of a combination of IL-15 and IL-12. A tumor-neutralizing (Winn) assay revealed that the antitumor activity of effector cells in the TEC was abrogated by treatment with anti-CD8 mAb or anti-asialoGM1 Ab plus complement. Thus, treatment with IL-15 in combination with IL-12 may enhance the activities of NK and CD8+ T cells in the TEC, providing strong antitumor activity against the malignant pleurisy. These results suggest that IL-15 together with IL-12 may have potential for the immunotherapy of some types of malignant pleurisy.

PubMed Disclaimer

Cited by

SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.
Cini JK, Dexter S, Rezac DJ, McAndrew SJ, Hedou G, Brody R, Eraslan RN, Kenney RT, Mohan P. Cini JK, et al. Front Immunol. 2023 Dec 20;14:1326927. doi: 10.3389/fimmu.2023.1326927. eCollection 2023. Front Immunol. 2023. PMID: 38250068 Free PMC article.
Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists.
Backhaus PS, Veinalde R, Hartmann L, Dunder JE, Jeworowski LM, Albert J, Hoyler B, Poth T, Jäger D, Ungerechts G, Engeland CE. Backhaus PS, et al. Viruses. 2019 Oct 3;11(10):914. doi: 10.3390/v11100914. Viruses. 2019. PMID: 31623390 Free PMC article.
Switching off malignant pleural effusion formation-fantasy or future?
Spella M, Giannou AD, Stathopoulos GT. Spella M, et al. J Thorac Dis. 2015 Jun;7(6):1009-20. doi: 10.3978/j.issn.2072-1439.2015.05.20. J Thorac Dis. 2015. PMID: 26150914 Free PMC article. Review.
Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.
Domvri K, Zarogoulidis P, Theodoropoulos F, Huang H, Zarogoulidis K. Domvri K, et al. Transl Lung Cancer Res. 2012 Sep;1(3):163-6. doi: 10.3978/j.issn.2218-6751.2012.08.02. Transl Lung Cancer Res. 2012. PMID: 25806177 Free PMC article. No abstract available.
Immunotherapy of cancer by IL-12-based cytokine combinations.
Weiss JM, Subleski JJ, Wigginton JM, Wiltrout RH. Weiss JM, et al. Expert Opin Biol Ther. 2007 Nov;7(11):1705-21. doi: 10.1517/14712598.7.11.1705. Expert Opin Biol Ther. 2007. PMID: 17961093 Free PMC article. Review.

Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model - PubMed (original) (raw)